Pan-Cancer Analysis of Enhancer-Induced PAN3-AS1 and Experimental Validation as a WFDC13-Promoting Factor in Colon Cancer
Oncology Research · 2026
DOI: 10.32604/or.2025.069274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Xu Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhejiang Hospital, Hangzhou, 310013, China. Hauptthemen laut MEDLINE: Colonic Neoplasms, RNA, Long Noncoding. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Zhejiang Hospital, Hangzhou, 310013, China.
- Clinical Research Center, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, China.
- Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, China.
Zitieren
APA
Guo, X., Yu, Y., Ma, X., & Cai, Y. (2026). Pan-Cancer Analysis of Enhancer-Induced PAN3-AS1 and Experimental Validation as a WFDC13-Promoting Factor in Colon Cancer. Oncology Research. https://doi.org/10.32604/or.2025.069274
Vancouver
Guo X, Yu Y, Ma X, Cai Y. Pan-Cancer Analysis of Enhancer-Induced PAN3-AS1 and Experimental Validation as a WFDC13-Promoting Factor in Colon Cancer. Oncology Research. 2026. doi:10.32604/or.2025.069274
BibTeX
@article{Guo2026,
author = {Guo, Xu and Yu, Yanan and Ma, Xiaolin and Cai, Yuanjie},
title = {Pan-Cancer Analysis of Enhancer-Induced PAN3-AS1 and Experimental Validation as a WFDC13-Promoting Factor in Colon Cancer},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2025.069274}
}
EUVIMED